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Abstract
Background: An antianginal KATP channel opener nicorandil has various beneficial effects on cardiovascular systems;
however, its effects on pulmonary vasculature under pulmonary arterial hypertension (PAH) have not yet been elucidated.
Therefore, we attempted to determine whether nicorandil can attenuate monocrotaline (MCT)-induced PAH in rats.
Materials and Methods: Sprague-Dawley rats injected intraperitoneally with 60 mg/kg MCT were randomized to receive
either vehicle; nicorandil (5.0 mg?kg
21?day
21) alone; or nicorandil as well as either a KATP channel blocker glibenclamide or
a nitric oxide synthase (NOS) inhibitor N
v-nitro-L-arginine methyl ester (L-NAME), from immediately or 21 days after MCT
injection. Four or five weeks later, right ventricular systolic pressure (RVSP) was measured, and lung tissue was harvested.
Also, we evaluated the nicorandil-induced anti-apoptotic effects and activation status of several molecules in cell survival
signaling pathway in vitro using human umbilical vein endothelial cells (HUVECs).
Results: Four weeks after MCT injection, RVSP was significantly increased in the vehicle-treated group (51.064.7 mm Hg),
whereas it was attenuated by nicorandil treatment (33.263.9 mm Hg; P,0.01). Nicorandil protected pulmonary
endothelium from the MCT-induced thromboemboli formation and induction of apoptosis, accompanied with both
upregulation of endothelial NOS (eNOS) expression and downregulation of cleaved caspase-3 expression. Late treatment
with nicorandil for the established PAH was also effective in suppressing the additional progression of PAH. These beneficial
effects of nicorandil were blocked similarly by glibenclamide and L-NAME. Next, HUVECs were incubated in serum-free
medium and then exhibited apoptotic morphology, while these changes were significantly attenuated by nicorandil
administration. Nicorandil activated the phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase
(ERK) pathways in HUVECs, accompanied with the upregulation of both eNOS and Bcl-2 expression.
Conclusions: Nicorandil attenuated MCT-induced vascular endothelial damage and PAH through production of eNOS and
anti-apoptotic factors, suggesting that nicorandil might have a promising therapeutic potential for PAH.
Citation: Sahara M, Sata M, Morita T, Hirata Y, Nagai R (2012) Nicorandil Attenuates Monocrotaline-Induced Vascular Endothelial Damage and Pulmonary Arterial
Hypertension. PLoS ONE 7(3): e33367. doi:10.1371/journal.pone.0033367
Editor: Carlo Gaetano, Istituto Dermopatico dell’Immacolata, Italy
Received November 19, 2011; Accepted February 13, 2012; Published March 30, 2012
Copyright:  2012 Sahara et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan to M. Sata (#17390227;
http://kaken.nii.ac.jp/) and by a research fellowship from the Japan Society for the Promotion of Science to M. Sahara. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: saharam-tky@umin.ac.jp
Introduction
Pulmonary arterial hypertension (PAH) is a progressive fatal
disorder with a poor prognosis [1,2]. The changes in the pulmonary
vasculature in PAH involve persistent vasoconstriction, vascular
smooth muscle cell proliferation, and thrombosis [1–3]. Although the
exact pathogenesis of PAH is still uncertain, it is thought that vascular
endothelial damage and dysfunction play a crucial role in triggering
pathological vascular remodeling [4]. In addition, experimental
studies suggest that endothelial cell apoptosis in pulmonary
microvasculaturecauses arteriolar occlusionandincreases pulmonary
vascular resistance [4–7], suggesting that vascular endothelial cell
apoptosis is closely associated with the pathogenesis of PAH.
Nicorandil is a unique hybrid vasodilator and exerts 2
vasodilator actions; adenosine triphosphate (ATP)-sensitive potas-
sium (KATP) channel opening and nitric oxide (NO) release [8].
Nicorandil is not only an antianginal drug but also exerts
cardioprotective effects on the ischemic myocardium due to its
KATP channel-opening action, thereby mimicking the phenome-
non of ischemic preconditioning [9]. Cumulative evidence suggests
that nicorandil has several beneficial effects on the cardiovascular
system; however, its effects on the pulmonary vasculature under
PAH remain undetermined.
On this basis, we evaluated the efficacy of nicorandil in an
experimental rat PAH model induced by monocrotaline (MCT).
Also, the mechanisms of action of nicorandil were investigated in
vivo and in vitro. Here, we show that nicorandil attenuates MCT-
induced endothelial damage and apoptosis in pulmonary vascu-
lature under PAH through production of endothelial NO synthase
(eNOS) and anti-apoptotic factors; the production is mediated by
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(PI3K)/Akt and extracellular signal-regulated kinase (ERK)
pathways, which are mainly activated via the opening of KATP
channels. The results suggest that nicorandil may have a
therapeutic potential for PAH.
Materials and Methods
Animals
Wild-type Sprague-Dawley rats were purchased from Japan
SLC. All experimental procedures and protocols were approved
by the Institutional Committee for Animal Research at the
University of Tokyo (#1621T 132) and complied with the Guide
for the Care and Use of Laboratory Animals (National Institutes of
Health (NIH) publication no. 86-23; revised 1985).
The animal model of PAH and experimental protocols
Eight-week-old male Sprague-Dawley rats were injected
intraperitoneally with saline (control) or 60 mg/kg MCT (Wako).
In the prevention protocol, the rats injected with MCT were
randomized to receive either a vehicle, nicorandil (2.5–
7.5 mg?kg
21?day
21) alone, or nicorandil (5.0 mg?kg
21?day
21)
with either 5.0 mg?kg
21?day
21 of the KATP channel blocker
glibenclamide or the NO synthase (NOS) inhibitor N
v-nitro-L-
arginine methyl ester (L-NAME; 1 mg/mL in drinking water) from
immediately after the MCT injection. The vehicle, nicorandil, and
glibenclamide were administered continuously by an implanted
subcutaneous osmotic pump (Alzet; Durect Corporation). Sepa-
rately, one group of the MCT-injected rats was administered a
pan-caspase inhibitor, Z-Val-Ala-Asp(OMe)-CH2F (ZVAD-fmk;
R&D Systems), as a bolus into the tail vein 4 times (first
immediately after the MCT injection and 1, 3, and 7 days later;
total dose, 3.3 mg/kg). In addition, the other group of the MCT-
injected rats was treated with a NO donor, sustained release
isosorbide dinitrate (sr-ISDN), by oral administration at a dose rate
of either 10, 50, or 100 mg?kg
21 once a day. Each group
comprised 8–10 rats. The right ventricular systolic pressure
(RVSP) of the rats was measured by inserting polyethylene
catheters into the right ventricle 28 days after the MCT injection.
The rats were then euthanized, and the hearts and lungs were
harvested. The weight ratio of the right ventricle (RV) to left
ventricle (LV) including the septum (RV/LV ratio) was deter-
mined. The right lungs were fixed in methanol or 4%
paraformaldehyde and embedded in paraffin for histological
analysis. The left lung segments were snap frozen in liquid
nitrogen for western blotting.
In the reversal protocol, the rats were injected with saline
(control) or 60 mg/kg MCT, and 21 days later, the rats were
randomized to receive either the vehicle, nicorandil
(5.0 mg?kg
21?day
21) alone, or nicorandil with glibenclamide or
L-NAME. Two weeks after the initiation of treatment, the RVSP
was measured, and the hearts and lungs were harvested for
analyses.
Survival Analysis
In a separate experiment, we examined the effects of nicorandil
on the survival of the MCT-injected rats in both the prevention
and reversal protocols. The day of the MCT injection was defined
as day 0, and the survival analysis observation continued up to day
42. The groups in both protocols comprised 12–15 rats.
Histological analysis
The paraffin-embedded sections were processed for hematox-
ylin and eosin, elastic Van Gieson, and immunohistochemical
staining for examination under light microscopy. The medial wall
thickness of the pulmonary arterioles (PAs) was calculated and
expressed as follows: %medial wall thickness=([medial thick-
ness62]/external diameter)6100. Immunohistochemical analyses
involved the incubation of the sections with the primary antibodies
(anti-a-smooth muscle actin [aSMA], Sigma; anti-CD68, Serotec;
and anti-eNOS, BD Biosciences), followed by incubation with a
biotinylated secondary antibody (Dako) using the avidin-biotin
complex technique with Vector Red substrate (Vector Laborato-
ries). The nuclei were counterstained with hematoxylin.
Terminal deoxynucleotidyl transferase-mediated 29-
deoxyuridine 59-triphosphate nick-end labeling staining
To detect apoptotic cell death, terminal deoxynucleotidyl
transferase-mediated 29-deoxyuridine 59-triphosphate (dUTP)
nick-end labeling (TUNEL) staining with immunofluorescence
staining for aSMA was performed using an in situ death detection
kit (Roche Molecular Biochemicals), as previously described [10].
Using a confocal microscope (FLUOVIEW FV300; Olympus), the
number of PAs (external diameter, 20–100 mm) having TUNEL-
positive endothelial cell(s) was counted in each lung cross section,
and the percentage was calculated as follows: ([the number of PAs
with TUNEL-positive endothelial cell(s)]/[a total number of
equally sized PAs (external diameter, 20–100 mm)]6100.
Immunohistochemical staining for Ki67 expression
To assess proliferation of smooth muscle cells (SMCs) in the
media of PAs, immunofluorescent double staining of lung frozen
sections for Ki67 and aSMA was performed. After blocking with
1% bovine serum albumin and 5% goat serum in PBS, the sections
were incubated overnight with anti-Ki67 rabbit antibody (Abcam)
and anti-aSMA mouse antibody (Sigma), followed by incubation
with Alexa Fluor 488-conjugated anti-rabbit IgG and Alexa Fluor
594-conjugated anti-mouse secondary antibodies (Molecular
Probes) for 1 h. After washing, the nuclei were counterstained
with DAPI (Sigma) before mounting and imaging by a confocal
microscope. The number of proliferating PA-SMCs with Ki67
positive nuclei was expressed as the percentage of Ki67-positive
cells over the total number of aSMA-positive SMCs in the media
of 30–40 PAs (external diameter, 20–100 mm) per rat.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were
purchased from Cambrex BioScience and were cultured in
endothelial growth medium-2 (EGM-2) (Clonetics) containing
2% fetal bovine serum (FBS) and growth factors. HUVECs were
grown to 80–90% confluence and were then starved in serum-free
medium. After 4 h, the serum-starved HUVECs were stimulated
with several agents; including nicorandil (10–1000 mmol/L); a
KATP channel opener, diazoxide (100 mmol/L; Chugai); or
nicorandil (100 mmol/L) with either glibenclamide (10 mmol/L),
L-NAME (2 mmol/L), a PI3K inhibitor, LY294002 (10 mmol/L;
Calbiochem), or an ERK-specific mitogen-activated protein kinase
kinase (MEK) inhibitor, PD98059 (10 mmol/L; Calbiochem); for
the indicated time intervals.
Analyses of cell morphology, viability, and apoptosis
HUVECs were incubated in a serum-free medium with or
without nicorandil for 48 h. The cells were then observed under a
phase contrast microscope (Olympus). Cell viability was deter-
mined using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2H-tetrazolium inner salt assay (MTS; Promega Corpo-
ration), and the percent cell death was calculated as follows:
Nicorandil Attenuates Pulmonary Hypertension
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33367Nicorandil Attenuates Pulmonary Hypertension
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e333671006{12[viability of treated (serum-starved) endothelial cells/
viability of untreated endothelial cells]}. In a separate series,
HUVECs that were incubated in serum-free medium for 12 h
were subjected to TUNEL staining to detect apoptotic cell death,
according to the manufacturer’s instructions. The nuclei were
counterstained with Hoechst 33258 (Sigma). TUNEL-positive
nuclei were counted in 10 randomly selected fields using a confocal
microscope (Olympus) and were expressed as a percentage of the
total number of nuclei.
Western blotting
Proteins were extracted from the lung tissues or HUVECs after
homogenization in a lysis buffer containing a protease inhibitor
cocktail (Sigma). The protein samples (5–10 mg) were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a polyvinylidene fluoride membrane
(Hybond-P; GE Healthcare). The membranes were incubated
with primary antibodies to eNOS, cleaved caspase-3, Akt, Ser473-
phospho-Akt, ERK, Thr202/Thr204-phospho-ERK1/2, Bad,
Ser112-phospho-Bad (Cell Signaling Technology), and Bcl-2 (BD
Biosciences), followed by incubation with a horseradish peroxi-
dase-conjugated secondary antibody. Next, an enhanced chemi-
luminescence system (ECL Plus; GE Healthcare) was used to
detect immunoblotting, and bands were visualized and quantified
with a lumino-analyzer (LAS-1000; Fujifilm). The signal intensity
was normalized to b-actin expression.
Akt kinase assay
Akt kinase activity was determined in the protein (20 mg)
extracted from the HUVEC lysates by detecting the phosphory-
lated glycogen synthase kinase (GSK)-3 fusion protein with the Akt
kinase assay kit (Cell Signaling Technology), according to the
manufacturer’s instructions.
Statistical analysis
Data are presented as the mean 6 standard deviation (SD). The
comparison of the means was performed by a one-way analysis of
variance (ANOVA) followed by Scheffe ´’s post hoc test. The
survival curves were analyzed by the Kaplan-Meier method and
compared using the Wilcoxon rank sum test. Statistical signifi-
cance was defined as P,0.05.
Results
Nicorandil prevents the progression of MCT-induced PAH
The RVSP in the vehicle-treated group in the prevention
protocol was significantly higher than that of the normal controls
at 28 days after the MCT injection (51.064.7 mm Hg vs.
20.262.8 mm Hg; P,0.01) (Figure 1A). Nicorandil attenuated
the MCT-induced increase in RVSP in a dose-dependent manner,
and the RVSP was 33.263.9 mm Hg in rats treated with
5.0 mg?kg
21?day
21 nicorandil (P,0.01 vs. the vehicle). The effect
of nicorandil was markedly inhibited by glibenclamide
(44.863.4 mm Hg) and L-NAME (45.664.8 mm Hg; P,0.05
vs. nicorandil alone). The pan-caspase inhibitor ZVAD-fmk also
attenuated the MCT-induced increase in RVSP
(33.063.1 mm Hg; P,0.01 vs. the vehicle). Further, the RV/
LV ratio, which was increased in the vehicle group, was also
significantly attenuated in the nicorandil- and ZVAD-fmk-treated
groups (Figure 1B). The systemic blood pressure and heart rate of
the rats did not vary among the groups (data not shown).
Histological analysis revealed that the percent medial wall
thickness of the PAs in the vehicle-treated group was significantly
greater than that of the normal controls (62.767.0% vs.
20.562.9%; P,0.01) (Figure 1C and 1D). Treatment with
5.0 mg?kg
21?day
21 nicorandil (32.063.4%) and ZVAD-fmk
(30.663.6%) attenuated the MCT-induced medial wall thickening
(P,0.01 vs. the vehicle, respectively); however, these effects of
nicorandil were inhibited by glibenclamide and L-NAME.
The survival analysis revealed that nicorandil significantly
improved the survival rate in the MCT-injected rats in the
prevention protocol (Figure 1E). The survival rates at 28 and 42
days after the MCT injection were 46% and 8% in the vehicle
group, and those were increased to 77% and 54% in the
nicorandil-treated group (5.0 mg?kg
21?day
21; P,0.05), respec-
tively, whereas the coadministration of glibenclamide or L-NAME
diminished the effect of nicorandil (Figure 1E).
In a separate series, the rats with MCT-induced PAH were
treated with a slow NO-releasing drug, sr-ISDN. Low and middle
doses of sr-ISDN (10 or 50 mg?kg
21?day
21) attenuated the MCT-
induced increase in RVSP (41.864.3 or 38.663.4 mm Hg;
P,0.05 vs. the vehicle) without changing systemic blood pressure
and heart rate, although the decreasing degree in RVSP was
modest compared with 5.0–7.5 mg?kg
21?day
21 nicorandil. High
dose of sr-ISDN (100 mg?kg
21?day
21) attenuated the MCT-
induced increase in RVSP to a greater degree (35.864.0 mm Hg;
P,0.01 vs. the vehicle); however, high dose of sr-ISDN also
significantly decreased systemic blood pressure in the rats with
MCT-induced PAH (74.468.8 mm Hg vs. 91.868.6 mm Hg in
the vehicle; P,0.01) and, probably due to the induction of severe
hypotension, did not improve the survival rate in the MCT-
injected rats (data not shown).
Nicorandil improves the histopathological findings in
MCT-injured lungs
Immunohistochemical findings revealed that nicorandil and
ZVAD-fmk attenuated both the thickening of the PA’s media that
was composed of aSMA-positive cells and the recruitment of
macrophages into the perivascular areas in MCT-injured lungs
(Figure 2A). MCT markedly impaired eNOS expression in the
endothelium of the pulmonary vasculature, and the expression was
restored by treatment with nicorandil and ZVAD-fmk (Figure 2A).
As shown in Figure 2B and 2D, MCT readily induced
thromboemboli formation and endothelial cell apoptosis in small
PAs (external diameter, 20–100 mm), and nicorandil and ZVAD-
fmk attenuated these deteriorated changes (Figure 2B–2E).
Treatment with nicorandil also significantly reduced the number
of proliferating SMCs with Ki67 positive nuclei in the media of
remodeled PAs (Figure 3). In contrast, glibenclamide and L-
NAME blocked these effects of nicorandil, respectively.
Figure 1. The effects of nicorandil in the prevention protocol. The RVSP (A) and the RV/LV ratio (B) 28 days after MCT injection are shown.
Treatment with nicorandil and ZVAD-fmk attenuated the MCT-induced increase in both these parameters, while these effects of nicorandil were
blocked by glibenclamide and L-NAME. Each group comprised 8–10 rats.
#P,0.01 vs. normal control;
*P,0.05 and
**P,0.01 vs. vehicle;
{P,0.05 and
{P,0.01 vs. nicorandil (5.0 mg?kg
21?day
21). (C) Histological findings of the PAs (arrows). Top, hematoxylin and eosin (HE) staining; bottom, elastic
Van Gieson (EVG) staining. Scale bar, 50 mm. (D) MCT markedly increased the percent medial wall thickness of the PAs (#), and nicorandil and ZVAD-
fmk attenuated MCT-induced medial wall thickening (**). In contrast, the effects of nicorandil were inhibited by glibenclamide and L-NAME ({). (E)
Survival analysis in the prevention protocol. Each group comprised 12–13 rats.
*P,0.05 vs. vehicle.
doi:10.1371/journal.pone.0033367.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33367Figure 2. Nicorandil improves the histopathological findings of MCT-injured lungs. (A) Immunohistochemical staining for aSMA (a), CD68
(b), and eNOS (c) in lung sections are shown. Histopathologically, MCT injury induced the thickened medial wall of PAs (arrows) that was composed
of aSMA-positive cells, the recruitment of CD68-positive macrophages into the perivascular areas, and the deficiency of eNOS expression in the
endothelium of the pulmonary vasculature (see vehicle). Nicorandil and ZVAD-fmk improved these deleterious histopathological changes in the MCT-
injured lungs, whereas glibenclamide and L-NAME blocked the effects of nicorandil. Scale bar, 50 mm. (B) MCT readily induced thromboemboli
formation that occluded the small PAs (arrows; see vehicle), which was attenuated by nicorandil. HE staining. Scale bars, 100 mm (top) and 50 mm
(bottom). (C) The number of small PAs that were occluded by thromboemboli was counted in the lung sections. (D) TUNEL staining with
immunofluorescence staining for aSMA in lung sections. MCT readily induced endothelial cell apoptosis (arrowheads) in a number of PAs (arrows; see
vehicle), which was attenuated by nicorandil. TUNEL (green); aSMA (red); and nuclei (blue). Scale bars, 100 mm (top) and 20 mm (bottom). (E) The
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downregulates cleaved caspase-3 expression in MCT-
injured lungs
Western blot analysis revealed that MCT significantly downreg-
ulated eNOS expression and inversely upregulated cleaved caspase-
3 expression in the lungs (Figure 4A). Notably, nicorandil as well as
ZVAD-fmk increased the expression of eNOS and attenuated the
expression of cleaved caspase-3 in MCT-injured lungs in a dose-
dependent manner, while these effects of nicorandil were also
blocked by glibenclamide and L-NAME (Figure 4B and 4C).
Nicorandil prevents the progression of established PAH
In the reversal protocol, we evaluated whether nicorandil was
also effective against established PAH. The RVSP and the RV/
LV ratio in the vehicle group increased to 38.764.7 mm Hg and
0.3360.06 at 21 days after the MCT injection (P,0.05 vs. the
normal control, respectively), and moreover, these parameters
increased to 55.064.6 mm Hg and 0.4760.04 at 35 days (P,0.01
vs. the normal control, respectively) (Figure 5A and 5B). Late
treatment with nicorandil on days 21–35 prevented the additional
increases in the RVSP and RV/LV ratio, as the values in the
nicorandil-treated group were 37.362.9 mm Hg and 0.3360.03
at day 35 (P,0.05 vs. the vehicle, respectively). Histological
analysis revealed that nicorandil prevented additional medial wall
thickening of the PAs in MCT-injured lungs (Figure 5C and 5D).
The survival analysis revealed that nicorandil improved the
survival rate in rats with established PAH in the reversal protocol
(Figure 5E). The survival rate at 42 days after the MCT injection
was 13% in the vehicle group and 40% in the nicorandil-treated
group (P,0.05). In contrast, these beneficial effects of nicorandil
were blocked by glibenclamide and L-NAME, respectively.
Restoration of eNOS expression by nicorandil in
established PAH
In the reversal protocol, MCT downregulated the expression of
eNOS in the endothelium of the pulmonary vasculature
(Figure 6A) and lung homogenates (Figure 6B and 6C) in a
time-dependent manner. Notably, late treatment with nicorandil
restored eNOS expression at least partially (Figure 6A–C), while
this effect was inhibited by glibenclamide and L-NAME.
Anti-apoptotic effects of nicorandil on in vitro vascular
endothelial cells
Next, we examined the in vitro anti-apoptotic effects of
nicorandil for vascular endothelial cells. HUVECs were cultured
in serum-free medium and then exhibited apoptotic morphology
that was characterized by cell shrinkage (Figure 7A), and there was
a decrease in the viability of these cells as determined by the MTS
assay (Figure 7B). In addition, there was an increase in the number
of serum-starved HUVECs that exhibited apoptotic morphology
as identified by TUNEL staining (Figure 7C and 7D). Stimulation
with nicorandil and the KATP channel opener diazoxide partially
inhibited the serum starvation-induced endothelial cell apoptosis
in a concentration-dependent manner, while these effects of
nicorandil were also inhibited by glibenclamide and L-NAME
(Figure 7A–D).
Nicorandil activates the PI3K/Akt and ERK pathways in
vascular endothelial cells
Both the PI3K/Akt and ERK signaling pathways function as
cell survival signaling cascades [11,12]. To investigate the signaling
pathways associated with the actions of nicorandil on vascular
endothelial cells, we determined the phosphorylation status of Akt
and ERK1/2 in the serum-starved HUVECs. Nicorandil
(100 mmol/L) induced Akt serine-473 phosphorylation in HU-
VECs in a time-dependent manner, with a maximum 3.0-fold
increase (Figure 8A and 8B). Diazoxide (100 mmol/L) also induced
a maximum 2.1-fold increase in Akt phosphorylation. The Akt
phosphorylation induced by nicorandil was blocked by glibencla-
mide (10 mmol/L) and a PI3K inhibitor, LY294002 (10 mmol/L).
To determine the Akt kinase activity, we measured the
phosphorylation of GSK-3, which is a downstream target of Akt.
number of small PAs having TUNEL-positive endothelial cell(s) [EC(s)] was counted in lung sections, and the proportion of PAs with TUNEL-positive
EC(s) in a total of equally sized PAs was calculated.
#P,0.01 vs. normal control;
*P,0.05 and
**P,0.01 vs. vehicle;
{P,0.05 and
{P,0.01 vs. nicorandil
(5.0 mg?kg
21?day
21).
doi:10.1371/journal.pone.0033367.g002
Figure 3. Nidorandil attenuates proliferation of PA-SMCs in
MCT-injured lungs. Immunofluorescent double staining of lung
frozen sections for Ki67 and aSMA was performed. The number of
proliferating PA-SMCs with Ki67 positive nuclei expressed as the
percentage of Ki67-positive cells over the total number of aSMA-
positive SMCs in the media of 30–40 PAs (external diameter, 20–
100 mm) per rat was significantly reduced by treatment with nicorandil
and ZVAD-fmk. In contrast, glibenclamide and L-NAME diminished the
effect of nicorandil, respectively.
#P,0.01 vs. normal control;
*P,0.05
and
**P,0.01 vs. vehicle;
{P,0.01 vs. nicorandil (5.0 mg?kg
21?day
21).
doi:10.1371/journal.pone.0033367.g003
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(P,0.05 vs. baseline), which was blocked by glibenclamide and
LY294002 (Figure 8A; bottom). Similarly, nicorandil and
diazoxide induced ERK1/2 threonine-202/204 phosphorylation
in HUVECs, with a maximum 2.8- and 2.1-fold increase,
respectively (Figure 8C and 8D). In addition, serine-112
phosphorylation of Bad, which is a downstream target of
ERK1/2, was induced by nicorandil and diazoxide (Figure 8C;
bottom), whereas the phosphorylation of ERK1/2 and Bad by
nicorandil was blocked by glibenclamide and a MEK inhibitor,
PD98059 (10 mmol/L).
Finally, we measured the expressions of eNOS and the
apoptosis inhibitor Bcl-2, which is a downstream target of the
PI3K/Akt and ERK1/2 pathways, in the serum-starved HUVECs
stimulated with nicorandil for 24 h. Notably, nicorandil upregu-
lated the expression of both eNOS and Bcl-2 in a concentration-
dependent manner (Figure 8E and 8F), whereas these effects of
nicorandil were blocked by glibenclamide, LY294002, and
PD98059. Diazoxide also increased the expression of eNOS and
Bcl-2, although the degree of the increase induced by diazoxide
was lesser than that by nicorandil.
Discussion
Our experiments revealed that nicorandil attenuated the
progression of MCT-induced PAH and improved the survival
rate in rats with MCT-induced PAH both in the prevention and
reversal protocols. These effects were accompanied by an
improvement in the severity of pulmonary vascular remodeling
that includes medial wall thickening with the increase of
proliferating SMCs, recruitment of macrophages into the
perivascular areas, thromboemboli formation in the pulmonary
Figure 4. Nicorandil restores the downregulated eNOS expression and attenuates the upregulated caspase-3 expression in MCT-
injured lungs. (A) The expressions of eNOS and cleaved caspase-3 in lungs were determined by western blotting. MCT significantly downregulated
the expression of eNOS and inversely upregulated the expression of cleaved caspase-3 (see vehicle). Nicorandil and ZVAD-fmk restored eNOS
expression and attenuated caspase-3 expression in MCT-injured lungs, which were blocked by glibenclamide and L-NAME. Bands were quantified
using a lumino-analyzer, and the data of eNOS (B) and caspase-3 (C) expressions were expressed as fold increases normalized to b-actin expression.
#P,0.01 vs. normal control;
*P,0.05 vs. vehicle;
{P,0.05 and
{P,0.01 vs. nicorandil (5.0 mg?kg
21?day
21).
doi:10.1371/journal.pone.0033367.g004
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33367microcirculation, and vascular endothelial cell apoptosis. These
effects of nicorandil were closely associated with the enhanced
expression of eNOS and anti-apoptotic factors in the vascular
endothelium of the lungs, while those were blocked by glibencla-
mide and L-NAME, suggesting that the beneficial effects of
nicorandil on pulmonary vasculature are mediated by the opening
of KATP channels and NOS. In addition, nicorandil induced the
activation of the cell survival signaling pathways, PI3K/Akt and
ERK1/2, in the vascular endothelial cells, resulting in the
production of eNOS and anti-apoptotic factors.
Nicorandil is a nicotinamide ester with 2 vasodilator actions—
KATP channel opening and NO release [8]. The Impact Of
Nicorandil in Angina (IONA) study has demonstrated that
nicorandil improves the clinical outcome of patients with stable
angina [13]. The mechanisms underlying the reduction in major
coronary events in the trial are thought to be related to the
cardioprotective effects of nicorandil that mimic ischemic
preconditioning through KATP channels. Although the effects of
nicorandil in PAH have remained undetermined, a few reports
based on animal studies [14] and clinical experience [15] have
suggested its potential efficacy for PAH treatment. In contrast to
our results, Hongo et al. [14] reported that late treatment with
nicorandil could not prevent further development of PAH nor
prolong survival in rats with established PAH. The reason for this
discrepancy remains unclear, but it may be attributable to the
difference in the injection method of nicorandil (drinking water or
subcutaneous osmotic pumps).
MCT, a pyrrolizidine alkaloid toxin, induces selective pulmo-
nary endothelial injury and apoptosis, followed by severe
inflammatory responses and medial hypertrophy [6,16]. In our
study, nicorandil protected the endothelium of the pulmonary
vasculature from MCT injury by both restoring eNOS expression
and inhibiting the induction of endothelial cell apoptosis in vivo
and in vitro. Cumulative evidence suggests that endothelial cell
apoptosis in pulmonary vasculature might trigger pathological
vascular remodeling, leading to the progression of PAH [4–7,10].
Consistent with the findings of a previous report [5], the broad
caspase inhibitor ZVAD-fmk also attenuated the development of
MCT-induced PAH in the present study, accompanied with a
decrease in endothelial cell apoptosis in the pulmonary microvas-
culature. It is plausible that the anti-apoptotic effects of nicorandil
and ZVAD-fmk on the pulmonary vascular endothelium might
contribute to the blocking of development of pathological
pulmonary vascular remodeling induced by MCT and therefore
Figure 5. The effects of nicorandil in the reversal protocol. The RVSP (A) and the RV/LV ratio (B) in the vehicle group increased at 21 days after
the MCT injection (MCT-21) as compared to the baseline, and additionally increased in the next 2 weeks (MCT-35). Late treatment with nicorandil on
days 21–35 prevented the additional increase in these parameters, while these effects were blocked by glibenclamide and L-NAME.
#P,0.05 and
##P,0.01 vs. normal control;
*P,0.05 and
**P,0.01 vs. vehicle (MCT-35);
{P,0.05 vs. nicorandil (5.0 mg?kg
21?day
21). (C) The histological findings of
the PAs (arrows) in the reversal protocol. Top, HE staining; bottom, EVG staining. Scale bar, 50 mm. (D) Late treatment with nicorandil on days 21–35
prevented further increase in the percent medial wall thickness of the PAs. The indications of the symbols are the same as those in panel (A). (E)
Survival analysis in the reversal protocol. Each group comprised 14–15 rats.
*P,0.05 vs. vehicle.
doi:10.1371/journal.pone.0033367.g005
Figure 6. Nicorandil restores eNOS expression in the pulmonary vascular endothelium in established PAH. (A) Immunohistochemical
staining for eNOS in lung sections in the reversal protocol. Arrows indicate the PAs. Scale bar, 50 mm. (B) Detection of eNOS expression in lungs by
western blotting in this protocol. MCT downregulated eNOS expression in a time-dependent manner, whereas late treatment with nicorandil resulted
in partial restoration of eNOS expression. (C) Bands in panel (B) were quantified, and eNOS expression data were expressed as fold increases
normalized to b-actin expression.
#P,0.01 vs. normal control;
##P,0.01 vs. normal control and P,0.05 vs. MCT-14;
*P,0.01 vs. MCT-35;
{P,0.01 vs.
nicorandil (5.0 mg?kg
21?day
21).
doi:10.1371/journal.pone.0033367.g006
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survival in rats with MCT-induced PAH. On the other hand,
medial hypertrophy itself by proliferation of vascular SMCs is also
a major histopathological finding in pulmonary vasculature under
PAH [1–3], and nicorandil seems to have the direct and/or
indirect effects on SMCs in the media of PAs as nicorandil
markedly reduced the number of proliferating SMCs (Figure 3).
Our results are consistent with the report demonstrating that
nicorandil has anti-proliferation effects on rat aortic SMCs [17].
Intriguingly, a specific anti-apoptotic reagent ZVAD-fmk also
attenuated proliferation of medial SMCs in the remodeled PAs in
the similar manner as nicorandil. Since we found no TUNEL-
positive apoptotic cells among proliferating medial SMCs in PAs
of the MCT-injured lungs (Figure 2D–E), it would appear that
ZVAD-fmk exerted anti-apoptotic effects on pulmonary vascular
endothelial cells, not on medial SMCs, in this setting, resulting in
the indirect anti-proliferation effects on medial SMCs. Taken
together, nicorandil might attenuate medial hypertrophy of PAs in
this model by not only the direct effect on PA-SMCs but also the
indirect effect through blocking the induction of apoptosis on the
pulmonary vascular endothelium. This notion is supported by the
results of the recent report that has revealed that the absence of
normal immune regulation results in an inappropriately exuberant
inflammatory response and accelerated endothelial cell apoptosis,
leading to smooth muscle hypertrophy and increased pulmonary
vascular resistance [18].
Although the anti-apoptotic effects of nicorandil on vascular
endothelial cells have not been reported so far, nicorandil is known
to exert anti-apoptotic effects on cardiomyocytes via the activation
of KATP channels [19]. The protective effects of nicorandil on the
pulmonary endothelium in our study were involved in the eNOS
production, and this finding is consistent with a previous study
[20] that revealed that nicorandil enhanced eNOS expression in
the myocardium via the opening of KATP channels. In our study,
the KATP channel closer glibenclamide inhibited the nicorandil’s
protective effects, including the enhanced expression of eNOS on
the pulmonary endothelium, suggesting that eNOS production
induced by nicorandil appeared to be a downstream event after
the opening of KATP channels. The notion is supported by the
findings of a previous report [21] that showed that a KATP channel
opener protected the myocardium against lethal ischemia via NOS
production.
The production of anti-apoptotic factors and eNOS by
nicorandil was associated with the activation of both the PI3K/
Akt and ERK1/2 signaling pathways. Indeed, the PI3K/Akt and
ERK1/2 signaling pathways play a crucial role in cell survival and
regulation of apoptosis [11,12]. Many downstream effectors in the
PI3K/Akt and ERK1/2 signaling pathways, including Bcl-2, Bad,
and the caspase family members, function as inhibitors of
apoptosis. Intriguingly, the ERK1/2 pathway has been reported
to undergo activation in response to reactive oxygen species (ROS)
[22], and the opening of mitochondrial KATP channels has been
shown to generate mitochondria-derived ROS in cardiomyocytes
[23]. Thus, owing to its KATP channel-opening property,
nicorandil may activate the ERK1/2 pathway via the generation
of ROS in the mitochondria in vascular endothelial cells, although
not addressed in this study; the notion is supported by evidence
from the literature that has shown that another KATP channel
opener diazoxide also triggers ERK activation through mitochon-
dria-derived ROS in cardiomyocytes [24]. On the contrary, the
Figure 7. Nicorandil prevents the induction of vascular endothelial cell apoptosis in vitro. (A) The HUVECs were incubated in the serum-
free medium in the absence or presence of nicorandil (10–1000 mmol/L) for 48 h. The serum-starved HUVECs exhibited apoptotic morphology, which
is characterized by cell shrinkage (see ‘‘serum starved’’). (B) The viability of the HUVECs was measured with the MTS assay, and the percent cell death
was calculated. Stimulation with nicorandil and diazoxide partially restored cell viability in a concentration-dependent manner. VEGF, vascular
endothelial growth factor (positive control).
*P,0.05 and
**P,0.01 vs. control (no drug). (C) TUNEL staining revealed that a large number of the
serum-starved HUVECs exhibited apoptotic morphology (left), and the apoptotic effects induced by serum starvation were attenuated by nicorandil
(middle). TUNEL (green); nuclei (blue). (D) The TUNEL-positive nuclei in the serum-starved HUVECs were counted in 10 randomly selected fields and
expressed as a percentage of the total number of nuclei.
**P,0.01 vs. control (no drug).
doi:10.1371/journal.pone.0033367.g007
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activate the PI3K/Akt pathway in the cardiomyocytes of rodents
as well [21,25]. In addition, NO has been shown to induce the
activation of both the PI3K/Akt and ERK1/2 signaling pathways
through a cyclic guanosine monophosphate-dependent pathway
[24,26]. Taking into consideration that the degree of the in vitro
effects induced by diazoxide in our study was lesser than that
induced by nicorandil, not only the KATP channel-opening effect
but also the NO-releasing property itself of nicorandil may
contribute to the activation of the PI3K/Akt and ERK1/2
pathways, resulting in the beneficial protective effects against
serum starvation in vitro and MCT injury in vivo.
NO is known to dilate the pulmonary vessels and used in the
short-term treatment of patients with severe PAH derived from a
variety of origins, although there is limited experience with the
long-term use of inhaled NO as a treatment of PAH [1,2,27]. In
the present study, a slow NO-releasing drug, sr-ISDN, also
attenuated MCT-induced PAH in rats to some degree; however,
the effects without changing systemic blood pressure and heart
rate were modest compared with nicorandil. Given that a KATP
channel closer glibenclamide inhibited approximately 60–70% of
the nicorandil’s protective effects for deteriorated pulmonary
vasculature and hemodynamics in rats with MCT-induced PAH, it
seems that the major beneficial effects of nicorandil are attributed
to its KATP channel opening property, while its NO donor
property functions adjunctively in this setting. Alternatively, the
feature as being a unique hybrid drug with the 2 vasodilator
actions may be a crucial advantage of nicorandil, at least in the
context of treatment of PAH.
In conclusion, the present study has revealed that nicorandil
attenuates MCT-induced vascular endothelial damage and
apoptosis and PAH through the production of eNOS and anti-
apoptotic factors, which is mediated by the PI3K/Akt and ERK1/
2 signaling pathways. These results strongly supports the notion
that nicorandil has a promising therapeutic potential for PAH.
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Figure 8. Nicorandil activates the PI3K/Akt and ERK pathways in HUVECs. (A) Nicorandil and diazoxide increased Akt serine-473 and GSK-3
phosphorylation in the serum-starved HUVECs, while these effects of nicorandil were blocked by glibenclamide and the PI3K inhibitor LY294002. (B)
The Akt phosphorylation (p-Akt) data are expressed as fold increases normalized to the total Akt (t-Akt) expression. IGF, insulin-like growth factor
(positive control).
**P,0.01 vs. control (no drug);
{P,0.01 vs. 60-min nicorandil treatment. (C) Nicorandil and diazoxide also increased ERK1/2
threonine-202/204 and Bad serine-112 phosphorylation in the HUVECs, while these effects of nicorandil were blocked by glibenclamide and the MEK
inhibitor PD98059. (D) The ERK phosphorylation (p-ERK) data are expressed as fold increases normalized to the total ERK (t-ERK) expression.
*P,0.05
and
**P,0.01 vs. control (no drug);
{P,0.05 and
{P,0.01 vs. 15-min nicorandil treatment. (E) In serum-starved HUVECs treated with nicorandil for
24 h, the expression of eNOS and Bcl-2 was upregulated in a concentration-dependent manner, while these effects were blocked by glibenclamide,
LY294002 (data not shown), and PD98059. (F) eNOS and Bcl-2 expression data are expressed as fold increases normalized to the b-actin expression.
*P,0.05 and
**P,0.01 vs. control (no drug);
{P,0.01 vs. 100-mmol/L nicorandil treatment.
doi:10.1371/journal.pone.0033367.g008
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